SCHEMBL3748237

SCHEMBL3748237

COC(=O)c1ccc(-c2ccccc2)c(C)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.63
SLC2A1 P11166 1/20 0.60
PTGS2 P35354 1/20 0.59
TSHR P16473 1/20 0.53
ESR2 Q92731 1/20 0.51
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
HTT P42858 1/20 0.49
ROCK2 O75116 1/20 0.48
ROCK1 Q13464 1/20 0.48
ALDH1A1 P00352 2/20 0.48
PPARA Q07869 1/20 0.48
KDM4E B2RXH2 1/20 0.48
PKM P14618 1/20 0.48
HPGD P15428 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
RAB9A P51151 2/20 0.47
MAPT P10636 1/20 0.47
CASP3 P42574 1/20 0.47
SENP8 Q96LD8 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2771823 0.92 PTGS2 (0.59) EGFRSLC2A1PTGS2TSHRMEN1
SCHEMBL28255681 0.90 SLC2A1 (0.63) EGFRSLC2A1PTGS2TSHRROCK2
SCHEMBL19608970 0.89 EGFR (0.76) EGFRSLC2A1PTGS2TSHRESR2
SCHEMBL7402540 0.89 SLC2A1 (0.56) EGFRSLC2A1PTGS2ROCK2ROCK1
SCHEMBL821283 0.87 PTGS2 (0.59) EGFRSLC2A1PTGS2TSHRMEN1
SCHEMBL10458005 0.86 PTGS2 (0.76) EGFRSLC2A1PTGS2TSHRMEN1
SCHEMBL16937873 0.86 TDP1 (0.57) EGFRSLC2A1TSHRMEN1KMT2A
SCHEMBL28905197 0.85 SLC2A1 (0.59) EGFRSLC2A1PTGS2TSHRALDH1A1
SCHEMBL6883774 0.85 HSD17B1 (0.59) EGFRSLC2A1PTGS2ESR2MEN1
SCHEMBL410258 0.85 PDK2 (0.51) EGFRSLC2A1PTGS2TSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122029148-A N-phenyl-3- (2, 5-dioxopyrrolidin-1-yl) propionamide derivatives and similar compounds as DUX4 inhibitors for the treatment of, for example, neuromuscular diseases 阿勒泰治疗公司 2026-05-12 CN disclosed
CN-119176777-A Cyclic alpha-hydroxyimide compound and application thereof 北京英飞智药科技有限公司 2024-12-24 CN disclosed
EP-2872490-B1 ANTIPROLIFERATIVE BENZO[B]AZEPIN-2-ONES HOFFMANN LA ROCHE (CH) 2018-02-07 EP disclosed
US-9695329-B2 Thermochromic color-memory composition and thermochromic color-memory microcapsule pigment encapsulating same THE PILOT INK CO., LTD. (JP) 2017-07-04 US disclosed
US-9611224-B2 Antiproliferative benzo [B] azepin-2-ones HOFFMANN-LA ROCHE INC. (US) 2017-04-04 US disclosed
US-20150353499-A1 ANTIPROLIFERATIVE BENZO [B] AZEPIN-2-ONES HOFFMAN-LA ROCHE INC. (US) 2015-12-10 US disclosed
CN-104703965-A Alpha hydroxy amides MERCK PATENT GMBH 2015-06-10 CN disclosed
EP-2872490-A1 ANTIPROLIFERATIVE BENZO [B]AZEPIN- 2 - ONES F. Hoffmann-La Roche AG (CH) 2015-05-20 EP disclosed
WO-2014009495-A1 ANTIPROLIFERATIVE BENZO [B] AZEPIN- 2 - ONES F. HOFFMANN-LA ROCHE AG (CH) 2014-01-16 WO disclosed
US-7838543-B2 Melanin Concentrating Hormone Receptor 1; Obesity; 4'-Fluoro-biphenyl-4-carboxylic acid {2-[(2-dimethylamino-ethyl)-methyl-amino]-benzothiazol-6-yl}amide; 4-Cyclohexyl-N-{2-[(2-dimethylamino-ethyl)-methyl-amino]-benzooxazol-5-yl}-benzamide; 2-aminobenzoxazoles or 2-aminobenzothiazoles ELI LILLY AND COMPANY (US) 2010-11-23 US disclosed
EP-1828177-B1 NOVEL MCH RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2008-08-13 EP disclosed
EP-1828177-B1 NOVEL MCH RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2008-08-13 EP disclosed
EP-1828177-A2 NOVEL MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2007-09-05 EP disclosed
WO-2006066173-A2 NOVEL MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2006-06-22 WO disclosed
EP-0905164-B1 Liquid crystalline polyester compositions and their uses NIPPON MITSUBISHI OIL CORP (JP) 2006-05-03 EP disclosed
CN-1751025-A Diamine derivatives DAIICHI SEIYAKU CO (JP) 2006-03-22 CN disclosed
US-5989758-A EXHIBIT A LIQUID CRYSTALLINE PHASE AT TIME OF FUSION, WHICH CAN BE FIXED UPON COOLING BELOW THE LIQUID CRYSTALLINE TRANSITION TEMPERATURE; SPECIFIC MONOMERS 4,4'-STILBENEDIOLS, CATECHOLS, AND 4'-HYDROXY-4-STILBENECARBOXYLIC ACIDS NIPPON OIL COMPANY, LIMITED (JP) 1999-11-23 US disclosed
EP-0905164-A2 Liquid crystalline polyesters, their composition, and their uses NIPPON OIL CO., LTD. (JP) 1999-03-31 EP disclosed
EP-0504732-B1 Powder coating composition NIPPON PAINT CO LTD (JP) 1996-06-19 EP disclosed
EP-0504732-A2 Powder coating composition Nippon Paint Co., Ltd. (JP) 1992-09-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353499-A1 ANTIPROLIFERATIVE BENZO [B] AZEPIN-2-ONES CCNY, RB1, TOP2B EGFR 433/4885SLC2A1 4478/4885PTGS2 2368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.